BRANFORD, Conn., Feb. 8 /PRNewswire-FirstCall/ -- Neurogen Corporation , a drug discovery and development company, announced today that Stephen R. Davis, Executive Vice President and Chief Operating Officer, will present a Company overview and pipeline update at the BIO CEO & Investor Conference 2006 on Wednesday, February 15 at 1:30 p.m. EST.
This presentation is being webcast live from the Waldorf Astoria Hotel in New York City and may be accessed through the investor relations section of the Company’s web site: www.neurogen.com. The webcast will be also be archived in this section until March 15, 2006, under “Events Calendar & Past Events Replay.”
About Neurogen
Neurogen Corporation targets new small molecule drugs to improve the lives of patients suffering from disorders with significant unmet medical need, including insomnia, pain, depression, obesity, and inflammation. Neurogen has generated a portfolio of compelling new drug candidates through its Accelerated Intelligent Drug Discovery (AIDD(TM)) system, its expertise in cellular functional assays, and its depth in medicinal chemistry. Neurogen conducts its research and development independently and, when advantageous, collaborates with world-class pharmaceutical companies to obtain additional resources and to access complementary expertise.
Neurogen Corporation
CONTACT: Elaine Grimsell Dodge, Neurogen Corp., +1-203-315-4615,edodge@nrgn.com
Web site: http://www.neurogen.com/
